326 related articles for article (PubMed ID: 32188241)
1. Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma.
Yu Z; Guo J; Hu M; Gao Y; Huang L
ACS Nano; 2020 Apr; 14(4):4816-4828. PubMed ID: 32188241
[TBL] [Abstract][Full Text] [Related]
2. Nanodelivery of scutellarin induces immunogenic cell death for treating hepatocellular carcinoma.
Li L; Zou Y; Wang L; Yang L; Li Y; Liao A; Chen Z; Yu Z; Guo J; Han S
Int J Pharm; 2023 Jul; 642():123114. PubMed ID: 37301243
[TBL] [Abstract][Full Text] [Related]
3. Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma.
Luo P; An Y; He J; Xing X; Zhang Q; Liu X; Chen Y; Yuan H; Chen J; Wong YK; Huang J; Gong Z; Du Q; Xiao W; Wang J
Cancer Lett; 2024 Apr; 587():216621. PubMed ID: 38242198
[TBL] [Abstract][Full Text] [Related]
4. Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer.
Xiao Y; Yao W; Lin M; Huang W; Li B; Peng B; Ma Q; Zhou X; Liang M
Drug Deliv; 2022 Dec; 29(1):1712-1725. PubMed ID: 35635307
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma.
Lu Y; Gao Y; Yang H; Hu Y; Li X
Mil Med Res; 2022 Dec; 9(1):69. PubMed ID: 36503490
[TBL] [Abstract][Full Text] [Related]
6. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma.
Wang Y; Yi Y; Yao J; Wan H; Yu M; Ge L; Zeng X; Wu M; Mei L
Acta Biomater; 2022 Nov; 153():518-528. PubMed ID: 36152910
[TBL] [Abstract][Full Text] [Related]
7. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
8. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
9. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
Fan Y; Li S; Ding X; Yue J; Jiang J; Zhao H; Hao R; Qiu W; Liu K; Li Y; Wang S; Zheng L; Ye B; Meng K; Xu B
BMC Cancer; 2019 Mar; 19(1):279. PubMed ID: 30922248
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma.
Chowdhury SM; Lee T; Bachawal SV; Devulapally R; Abou-Elkacem L; Yeung TA; Wischhusen J; Tian L; Dahl J; Paulmurugan R; Willmann JK
J Control Release; 2018 Jul; 281():19-28. PubMed ID: 29758233
[TBL] [Abstract][Full Text] [Related]
12. A fully biodegradable spherical nucleic acid nanoplatform for self-codelivery of doxorubicin and miR122 for innate and adaptive immunity activation.
Jiang MC; Fang ZL; Zhang JY; Ma W; Liao LF; Yu CY; Wei H
Acta Biomater; 2024 May; 180():407-422. PubMed ID: 38614414
[TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line.
Pho-Iam T; Punnakitikashem P; Somboonyosdech C; Sripinitchai S; Masaratana P; Sirivatanauksorn V; Sirivatanauksorn Y; Wongwan C; Nguyen KT; Srisawat C
Biochem Biophys Res Commun; 2021 May; 553():191-197. PubMed ID: 33774221
[TBL] [Abstract][Full Text] [Related]
14. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
[TBL] [Abstract][Full Text] [Related]
15. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
Chen Y; Chen HN; Wang K; Zhang L; Huang Z; Liu J; Zhang Z; Luo M; Lei Y; Peng Y; Zhou ZG; Wei Y; Huang C
J Hepatol; 2019 Jan; 70(1):66-77. PubMed ID: 30287340
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
18. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
